Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Forum Arrowhead Research geopend
Volgen
2019 will be productive Expect 2 new CTAs • ARO-HIF2 • ARO-ENaC • Expect to be in Phase 2 or later with 3 wholly-owned candidates • ARO-AAT, ARO-ANG3, ARO-APOC3 • Expect progress with partnered clinical candidates • ARO-HBV, AMG 890 • Wildcards • New Janssen targets • Amgen undisclosed CV target • Muscle targeting • ARWR breakthroughsir.arrowheadpharma.com/static-files/a...
Flinke dalingen recentelijk. Mogelijkheid voor rebounce naar 17$ juist, of wachten tot de $10,-? Ik snap niet zo goed waarom, lijkt mij een fundament liggen dankzij J&J.
Roofer schreef op 20 november 2018 15:46 :
Flinke dalingen recentelijk.
Mogelijkheid voor rebounce naar 17$ juist, of wachten tot de $10,-?
Ik snap niet zo goed waarom, lijkt mij een fundament liggen dankzij J&J.
Heb je de rest van de markten gezien laatste dagen? Dan snap ik wel waarom hoor! Ook de bio gaat dan gewoon mee omlaag dus geen idee hoever het nog kan dalen! J&J is een mooi bericht maar zullen gewoon goede onderzoeksresultaten moeten komen om de $ 20.00 plus op de borden te krijgen.
www.nasdaq.com/symbol/arwr/institutio... Flinke uitbreiding door institutionele beleggers. Er breekt nu waarschijnlijk paniek uit bij de shorts ( ca 17 miljoen). Stijging is nu al 5% Op naar de $ 20 zou ik zeggen.
Straks moet Intellia nog aankloppen bij Arrowhead voor gebruikmaking van het Trim platform. Bij de Crispr-Cas9 bedrijven bestaat de nijpende noodzaak voor een aangepast vehikel om de dna segmenten veilig een cel in te krijgen:www.ncbi.nlm.nih.gov/pmc/articles/PMC...
Vandaag misschien wat nieuws tijdens de presentatie van de cijfers!
Tís maar dat u het weet: Arrowhead Pharmaceuticals (ARWR) Price Target Raised to $165.00 at Cantor Fitzgerald Posted by ABMN Staff on Dec 17th, 2018 //
Arrowhead Pharmaceuticals (ARWR) Price Target Raised to $165.00 Posted by Lisa Matthews on Dec 17th, 2018 Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals (NASDAQ:ARWR) had its target price upped by stock analysts at Cantor Fitzgerald from $145.00 to $165.00 in a report issued on Monday. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Other equities analysts have also issued reports about the company. Chardan Capital reiterated a “buy” rating and issued a $24.50 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday. B. Riley upgraded Arrowhead Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $18.00 to $19.00 in a research note on Thursday, September 6th. William Blair reiterated an “outperform” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 17th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $25.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, October 4th. Finally, Jefferies Financial Group lifted their price objective on Arrowhead Pharmaceuticals to $24.00 and gave the stock a “buy” rating in a research note on Friday, September 14th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $44.86. Get Arrowhead Pharmaceuticals alerts: Shares of Arrowhead Pharmaceuticals stock traded down $0.11 during trading on Monday, reaching $14.21. The company’s stock had a trading volume of 235,649 shares, compared to its average volume of 1,321,183. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.37 and a current ratio of 6.37. The firm has a market capitalization of $1.32 billion, a PE ratio of -21.86 and a beta of 2.05. Arrowhead Pharmaceuticals has a one year low of $3.08 and a one year high of $22.39. Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, December 11th. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. The business had revenue of $11.26 million for the quarter, compared to analyst estimates of $3.73 million. Arrowhead Pharmaceuticals had a negative return on equity of 57.18% and a negative net margin of 337.32%. Research analysts forecast that Arrowhead Pharmaceuticals will post 1.34 earnings per share for the current year. In related news, CEO Christopher Richard Anzalone sold 90,000 shares of the business’s stock in a transaction dated Wednesday, December 12th. The stock was sold at an average price of $14.07, for a total transaction of $1,266,300.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Peter Brian Leone sold 131,137 shares of the business’s stock in a transaction dated Friday, October 19th. The shares were sold at an average price of $13.49, for a total value of $1,769,038.13. Following the transaction, the vice president now owns 160,000 shares in the company, valued at $2,158,400. The disclosure for this sale can be found here. Insiders sold 305,637 shares of company stock worth $4,246,343 over the last quarter. 4.60% of the stock is currently owned by corporate insiders. A number of institutional investors and hedge funds have recently modified their holdings of ARWR. RTW Investments LP increased its stake in Arrowhead Pharmaceuticals by 184.6% during the second quarter. RTW Investments LP now owns 8,299,542 shares of the biotechnology company’s stock valued at $112,874,000 after acquiring an additional 5,382,981 shares during the period. BlackRock Inc. increased its stake in Arrowhead Pharmaceuticals by 108.1% during the second quarter. BlackRock Inc. now owns 7,083,926 shares of the biotechnology company’s stock valued at $96,342,000 after acquiring an additional 3,679,986 shares during the period. FMR LLC bought a new position in Arrowhead Pharmaceuticals during the third quarter valued at about $37,922,000. Northern Trust Corp increased its stake in Arrowhead Pharmaceuticals by 380.1% during the second quarter. Northern Trust Corp now owns 1,063,499 shares of the biotechnology company’s stock valued at $14,464,000 after acquiring an additional 841,982 shares during the period. Finally, First Manhattan Co. increased its stake in Arrowhead Pharmaceuticals by 11.6% during the third quarter. First Manhattan Co. now owns 5,053,925 shares of the biotechnology company’s stock valued at $96,883,000 after acquiring an additional 523,675 shares during the period. Hedge funds and other institutional investors own 63.33% of the company’s stock.
$ 165.00 doe ik het wel voor ;) RECRUITING ARO-ANG3 trouwens! Positief allemaal en met de slechte beursweken valt de koersdaling nog mee! Eindejaarsrally en we staan op de $ 20.00 ;)clinicaltrials.gov/ct2/history/NCT037...
drulletje drie schreef op 2 januari 2019 09:24 :
seekingalpha.com/article/4230817-arro... Arrowhead heeft blijkbaar geen geneesmiddelen boven Fase 1 en dat vind ik zeer teleurstellend als je bedenkt hoelang dit bedrijf al bestaat.
DeZwarteRidder schreef op 2 januari 2019 09:29 :
[...]
Arrowhead heeft blijkbaar geen geneesmiddelen boven Fase 1 en dat vind ik zeer teleurstellend als je bedenkt hoelang dit bedrijf al bestaat.
arrowheadpharma.com/pipeline/
2 PB's die doen vermoeden dat het met de longterm Tox wel snor zit: Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseasesir.arrowheadpharma.com/press-releases
PB'tje Oppenheimer heeft flink uitgebreid, naar 8.5% wederom een goed signaal
Short interest een beetje gezakt met 1 mln. stukjes tot iets meer dan 17 mln. Blijft hoog. Gisteren nabeurs nog doorgestegen tot $13,97.
KeepTHeFaith schreef op 26 januari 2019 12:44 :
Gisteren nabeurs nog doorgestegen tot $13,97.
Met een stevig nabeurs volume van 550k
nelis h schreef op 26 januari 2019 21:17 :
[...]
Met een stevig nabeurs volume van 550k
Zelfs vandaag al voorbeurs handel dat is wel heel vroeg ;) Volume van niets hoor maar goed.www.nasdaq.com/symbol/arwr/premarket
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee